Tessa Therapeutics Competitors and Similar CompaniesClear all
Tessa Therapeutics's competitors and similar companies include Gradalis, Immatics, Cryo-Cell and Vericel.
 Tessa Therapeutics Tessa Therapeutics is a clinical-stage biotechnology company focused on the cancer treatment development. |  Gradalis Gradalis is a biotechnology company focused on the development and commercialization of personalized therapeutics to treat cancer. |  Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. |  Cryo-Cell Cryo-Cell International is a provider of cord blood banking and cord tissue storage services. |  Vericel Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. | |
Founding Date | Founding Date 2011 | Founding Date 2003 | Founding Date N/A | Founding Date 1989 | Founding Date 1989 |
Type | Type Private | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Singapore, SG HQ | Locations Carrollton, US HQ | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Oldsmar, US HQ Santiago, CL San Pedro Sula, HN Guadalajara, MX Panamá City, PA North Miami Beach, US Caracas, VE | Locations Cambridge, US HQ Ann Arbor, US |
Employees | Employees 432% increase | Employees 25 | Employees 29723% increase | Employees 804% decrease | Employees 24112% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1.1 b | Valuation ($) 47.9 m | Valuation ($) 2.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) €48.3m (FY, 2025) | Revenue (est.) $31.6m (FY, 2025) | Revenue (est.) $276.3m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $7.4m (FY, 2025) | Cost of goods $70.7m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit €53m (FY, 2025) | Gross profit $24.2m (FY, 2025) | Gross profit $205.6m (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income (€196.4m) (FY, 2025) | Net income ($2.4m) (FY, 2025) | Net income $16.5m (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 80m (over 8 years ago) | Latest funding round $ 43.9m (about 8 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 80m | Total funding raised $ 67.9m | Total funding raised $ 267.3m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Gradalis
HQ
Carrollton, US
Employees
25
Gradalis is a biotechnology company focused on the development and commercialization of personalized therapeutics to treat cancer.
View companyImmatics
HQ
Tübingen, DE
Employees
297↑ 23% increase
Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View companyCryo-Cell
HQ
Oldsmar, US
Employees
80↓ 4% decrease
Cryo-Cell International is a provider of cord blood banking and cord tissue storage services.
View companyVericel
HQ
Cambridge, US
Employees
241↑ 12% increase
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions.
View company